Repligen Corporation $RGEN Shares Bought by Synovus Financial Corp

Key Points

• Synovus Financial Corp increased its stake in Repligen Corporation by 153.0%, holding 16,543 shares valued at approximately $2.1 million as of its latest SEC filing.
• Several institutional investors, including Dimensional Fund Advisors LP and Northern Trust Corp, have also significantly increased their positions in Repligen during the fourth quarter, showcasing strong institutional interest.
• Analysts have mixed views on Repligen's stock, with price targets ranging from $130.00 to $204.00, and a consensus rating of "Moderate Buy."

Synovus Financial Corp grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 153.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,543 shares of the biotechnology company's stock after buying an additional 10,005 shares during the period. Synovus Financial Corp's holdings in Repligen were worth $2,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of RGEN. Raiffeisen Bank International AG purchased a new stake in Repligen during the 4th quarter worth about $29,000. Itau Unibanco Holding S.A. purchased a new stake in Repligen during the 4th quarter worth about $40,000. Signaturefd LLC lifted its holdings in Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares during the last quarter. Center for Financial Planning Inc. lifted its holdings in shares of Repligen by 110.3% in the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 193 shares during the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of Repligen by 99.4% in the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 332 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

RGEN traded up $0.15 on Monday, hitting $122.32. 651,937 shares of the company traded hands, compared to its average volume of 722,374. The company has a 50 day moving average of $121.79 and a 200-day moving average of $129.92. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $6.88 billion, a PE ratio of -489.26, a PEG ratio of 2.25 and a beta of 1.07. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on RGEN. HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Wells Fargo & Company reduced their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a report on Wednesday, July 30th. Barclays began coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 target price for the company. Finally, Stephens raised Repligen to an "overweight" rating and set a $160.00 target price for the company in a report on Tuesday, July 22nd. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $169.45.

Insider Buying and Selling

In related news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.